Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines

Robert Stearman, Michael C. Grady, Patrick Nana-Sinkam, Marileila Varella-Garcia, Mark W. Geraci

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The importance of the arachidonic acid pathway has been established in colon and lung cancers, as well as in inflammatory diseases. In these diseases, prostacyclin I2 (PGI2) and prostaglandin E2 (PGE2) are thought to have antagonistic activities, with PGI2 exerting anti-inflammatory and antiproliferative activities, whereas PGE2 is proinflammatory and antiapoptotic. In human lung cancer, prostacyclin synthase (PGIS) and PGI2 are down-regulated, whereas PGE2 synthase (PGES) and PGE2 are up-regulated. Murine carcinogenesis models of human lung cancer reciprocate the relationship between PGIS and PGES expression. PGIS-overexpressing transgenic mice are protected from carcinogen- and tobacco smoke-induced lung tumor formation, suggesting that PGI2 may play a role in chemoprevention. We investigated several potential mechanisms for the down-regulation of PGIS in human lung cancer. Using transcription reporter assays, we show that single nucleotide polymorphisms in the PGIS promoter can affect transcriptional activity. In addition, PGIS expression in several human lung cancer cell lines is silenced by CpG methylation, and we have mapped these sites across the variable number of tandem repeats (VNTR) sequence in the promoter, as well as CpGs within exon 1 and the first intron. Finally, using fluorescence in situ hybridization, we show that human lung cancer cell lines and lung cancer tissues do not have a loss of the PGIS genomic region but multiple copies. These results show that an individual's PGIS promoter haplotype can play an important role in the predisposition for lung cancer and CpG methylation provides an epigenetic mechanism for the down-regulated PGIS expression.

Original languageEnglish (US)
Pages (from-to)295-308
Number of pages14
JournalMolecular Cancer Research
Volume5
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Epigenomics
Lung Neoplasms
Epoprostenol
Cell Line
Dinoprostone
Methylation
Minisatellite Repeats
Tandem Repeat Sequences
prostacyclin synthetase
Chemoprevention
Fluorescence In Situ Hybridization
Arachidonic Acid
Smoke
Carcinogens
Colonic Neoplasms
Introns
Haplotypes
Transgenic Mice
Tobacco
Single Nucleotide Polymorphism

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines. / Stearman, Robert; Grady, Michael C.; Nana-Sinkam, Patrick; Varella-Garcia, Marileila; Geraci, Mark W.

In: Molecular Cancer Research, Vol. 5, No. 3, 03.2007, p. 295-308.

Research output: Contribution to journalArticle

Stearman, Robert ; Grady, Michael C. ; Nana-Sinkam, Patrick ; Varella-Garcia, Marileila ; Geraci, Mark W. / Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines. In: Molecular Cancer Research. 2007 ; Vol. 5, No. 3. pp. 295-308.
@article{d257f04a25e34cad9bfbb9fa226fa0ca,
title = "Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines",
abstract = "The importance of the arachidonic acid pathway has been established in colon and lung cancers, as well as in inflammatory diseases. In these diseases, prostacyclin I2 (PGI2) and prostaglandin E2 (PGE2) are thought to have antagonistic activities, with PGI2 exerting anti-inflammatory and antiproliferative activities, whereas PGE2 is proinflammatory and antiapoptotic. In human lung cancer, prostacyclin synthase (PGIS) and PGI2 are down-regulated, whereas PGE2 synthase (PGES) and PGE2 are up-regulated. Murine carcinogenesis models of human lung cancer reciprocate the relationship between PGIS and PGES expression. PGIS-overexpressing transgenic mice are protected from carcinogen- and tobacco smoke-induced lung tumor formation, suggesting that PGI2 may play a role in chemoprevention. We investigated several potential mechanisms for the down-regulation of PGIS in human lung cancer. Using transcription reporter assays, we show that single nucleotide polymorphisms in the PGIS promoter can affect transcriptional activity. In addition, PGIS expression in several human lung cancer cell lines is silenced by CpG methylation, and we have mapped these sites across the variable number of tandem repeats (VNTR) sequence in the promoter, as well as CpGs within exon 1 and the first intron. Finally, using fluorescence in situ hybridization, we show that human lung cancer cell lines and lung cancer tissues do not have a loss of the PGIS genomic region but multiple copies. These results show that an individual's PGIS promoter haplotype can play an important role in the predisposition for lung cancer and CpG methylation provides an epigenetic mechanism for the down-regulated PGIS expression.",
author = "Robert Stearman and Grady, {Michael C.} and Patrick Nana-Sinkam and Marileila Varella-Garcia and Geraci, {Mark W.}",
year = "2007",
month = "3",
doi = "10.1158/1541-7786.MCR-06-0221",
language = "English (US)",
volume = "5",
pages = "295--308",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines

AU - Stearman, Robert

AU - Grady, Michael C.

AU - Nana-Sinkam, Patrick

AU - Varella-Garcia, Marileila

AU - Geraci, Mark W.

PY - 2007/3

Y1 - 2007/3

N2 - The importance of the arachidonic acid pathway has been established in colon and lung cancers, as well as in inflammatory diseases. In these diseases, prostacyclin I2 (PGI2) and prostaglandin E2 (PGE2) are thought to have antagonistic activities, with PGI2 exerting anti-inflammatory and antiproliferative activities, whereas PGE2 is proinflammatory and antiapoptotic. In human lung cancer, prostacyclin synthase (PGIS) and PGI2 are down-regulated, whereas PGE2 synthase (PGES) and PGE2 are up-regulated. Murine carcinogenesis models of human lung cancer reciprocate the relationship between PGIS and PGES expression. PGIS-overexpressing transgenic mice are protected from carcinogen- and tobacco smoke-induced lung tumor formation, suggesting that PGI2 may play a role in chemoprevention. We investigated several potential mechanisms for the down-regulation of PGIS in human lung cancer. Using transcription reporter assays, we show that single nucleotide polymorphisms in the PGIS promoter can affect transcriptional activity. In addition, PGIS expression in several human lung cancer cell lines is silenced by CpG methylation, and we have mapped these sites across the variable number of tandem repeats (VNTR) sequence in the promoter, as well as CpGs within exon 1 and the first intron. Finally, using fluorescence in situ hybridization, we show that human lung cancer cell lines and lung cancer tissues do not have a loss of the PGIS genomic region but multiple copies. These results show that an individual's PGIS promoter haplotype can play an important role in the predisposition for lung cancer and CpG methylation provides an epigenetic mechanism for the down-regulated PGIS expression.

AB - The importance of the arachidonic acid pathway has been established in colon and lung cancers, as well as in inflammatory diseases. In these diseases, prostacyclin I2 (PGI2) and prostaglandin E2 (PGE2) are thought to have antagonistic activities, with PGI2 exerting anti-inflammatory and antiproliferative activities, whereas PGE2 is proinflammatory and antiapoptotic. In human lung cancer, prostacyclin synthase (PGIS) and PGI2 are down-regulated, whereas PGE2 synthase (PGES) and PGE2 are up-regulated. Murine carcinogenesis models of human lung cancer reciprocate the relationship between PGIS and PGES expression. PGIS-overexpressing transgenic mice are protected from carcinogen- and tobacco smoke-induced lung tumor formation, suggesting that PGI2 may play a role in chemoprevention. We investigated several potential mechanisms for the down-regulation of PGIS in human lung cancer. Using transcription reporter assays, we show that single nucleotide polymorphisms in the PGIS promoter can affect transcriptional activity. In addition, PGIS expression in several human lung cancer cell lines is silenced by CpG methylation, and we have mapped these sites across the variable number of tandem repeats (VNTR) sequence in the promoter, as well as CpGs within exon 1 and the first intron. Finally, using fluorescence in situ hybridization, we show that human lung cancer cell lines and lung cancer tissues do not have a loss of the PGIS genomic region but multiple copies. These results show that an individual's PGIS promoter haplotype can play an important role in the predisposition for lung cancer and CpG methylation provides an epigenetic mechanism for the down-regulated PGIS expression.

UR - http://www.scopus.com/inward/record.url?scp=34247157657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247157657&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-06-0221

DO - 10.1158/1541-7786.MCR-06-0221

M3 - Article

C2 - 17374734

AN - SCOPUS:34247157657

VL - 5

SP - 295

EP - 308

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 3

ER -